|
|
Article: Adolor Corporation Announces Positive Top-Line Results in 2nd Phase 3 Study of Alvimopan in Postoperative Ileus; - Primary Endpoint Statistically Significant in 6 mg and 12 mg Doses - - Conference Call and Webcast at 8:45 a.m. EDT on September 23, 2003 -.
- Article from:
- PR Newswire
- Article date:
- September 23, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Adolor Corporation announced today top-line results of its second Phase 3 clinical study (14CL313) of Entereg(TM) (alvimopan) in the management of postoperative ileus (POI). A statistically significant difference was achieved in the primary endpoint of the study, time to recovery of gastrointestinal function, in the Entereg(TM) (alvimopan) 6 mg and 12 mg treatment groups when each is compared to the placebo group.
"We are very excited to report today's positive results in both the 6 mg and 12 mg treatment groups, and believe they support our goal of submitting a New Drug Application for Entereg(TM) (alvimopan) to the U.S. Food and Drug Administration late in ...